SCHEMBL22191402

SCHEMBL22191402

O=c1[nH]c2ccc(-c3cncc(NCc4ccccc4F)c3)cc2[nH]1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 8/20 0.67
▸ MAPT P10636 7/20 0.67
▸ L3MBTL1 Q9Y468 3/20 0.48
▸ DYRK1A Q13627 1/20 0.44
▸ TP53 P04637 1/20 0.43
▸ LMNA P02545 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ THRB P10828 1/20 0.43
▸ CDK7 P50613 2/20 0.42
▸ PDE3B Q13370 1/20 0.42
▸ PDE3A Q14432 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ AKT1 P31749 1/20 0.42
▸ GRIA1 P42261 1/20 0.41
▸ CACNG8 Q8WXS5 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22191473 0.87 GAA (0.53) GAAMAPTL3MBTL1DYRK1AMEN1
SCHEMBL22191227 0.85 PDE3B (0.47) GAAMAPTKMT2ACDK7PDE3B
SCHEMBL22191663 0.85 GAA (0.46) GAAMAPTL3MBTL1DYRK1ALMNA
SCHEMBL22191401 0.83 GAA (0.46) GAAMAPTDYRK1ATP53LMNA
SCHEMBL29664810 0.83 GAA (0.45) GAAMAPTL3MBTL1MEN1KMT2A
SCHEMBL22191410 0.83 MAPT (0.50) GAAMAPTL3MBTL1DYRK1ATP53
SCHEMBL22190920 0.83 GAA (0.64) GAAMAPTL3MBTL1DYRK1ATP53
SCHEMBL22191691 0.83 PLK4 (0.48) GAAMAPTMEN1KMT2ACDK7
SCHEMBL22191838 0.82 CCNT1 (0.48) GAAMAPTDYRK1AMEN1KMT2A
SCHEMBL24137846 0.81 CDK7 (0.52) GAAMAPTDYRK1ACDK7AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3906233-B1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL MED MOUNT SINAI (US) 2024-01-31 — — EP disclosed
US-20220162182-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-05-26 — — US disclosed
US-20220162182-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-05-26 — — US disclosed
EP-3906233-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE Icahn School of Medicine at Mount Sinai (US) 2021-11-10 — — EP disclosed
CN-113508111-A Kinase inhibitor compounds and compositions and methods of use 西奈山伊坎医学院 2021-10-15 — — CN disclosed
WO-2020142485-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2020-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220162182-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE MAP3K20, MAP3K1, PACSIN2 GAA 829/4885MAPT 1320/4885L3MBTL1 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback